{"disease":{"id":"lung-cancer-biliary-tract-cancer","name":"lung cancer biliary tract cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04068168","title":"Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)","phase":"","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT02443324","title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04234113","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":115,"lead_sponsor_name":"SOTIO Biotech AG","has_results":true},{"nct_id":"NCT04733521","title":"A Phase 1/2 Study of SC-43 in Combination With Cisplatin","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"RaND Biosciences","has_results":false},{"nct_id":"NCT02586987","title":"A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05116891","title":"A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Cantargia AB","has_results":false},{"nct_id":"NCT05012397","title":"Milademetan in Advanced/Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Rain Oncology Inc","has_results":true},{"nct_id":"NCT06084689","title":"Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Institut Bergonié","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}